atg_gcg_aca_aca

> (Bike lanes) are designed for people with less active riding styles. Elderly people, kids, women.

Agreed women are underrepresented, but I don't think your statement is helping change the perception that women aren't real cyclists. Bike lanes are designed for people with less active riding style. Elderly people, kids, women, and men.

Uhhh... women?

Here's the Sequencing & Moore's Law plot that I'm tired of seeing in every genome sequencing presentation ever. https://wi-images.condecdn.net/image/W5YlBgPjX36/crop/1620

Since 2013, Illumina's brought the price of a genome to about $1k with the HiSeq X, which essentially scales up their existing tech. No idea what the next few years hold, but I'm excited to see insurance companies beginning to cover genome sequencing as an affordable diagnostic tool.

A few years ago, the sequencing field was really excited for this platform as an alternative/competitor to Illumina. Unfortunately, the MinION platform has never been able to generate enough high-quality data for most eukaryotic sequencing use cases. The MinION still has it's niche... long read sequencing can resolve problematic regions of the genome, and the minION is the only option for rapid sequencing in the field. For production genome sequencing centers though, Illumina's still the dominant tech. Their HiSeq X platform can put out a human genome right about $1k.